Preclinical Data on ARIAD's Oncology Pipeline to Be Presented at the AACR Annual Meeting.CAMBRIDGE, Mass. -- ARIAD ARIAD Allison Research Index of Art and Design Pharmaceuticals, Inc. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on : ARIA) today announced that new preclinical data on deforolimus, its investigational mTOR inhibitor, AP24534, its investigational multi-targeted kinase inhibitor, and its investigational anaplastic an·a·plas·tic adj. 1. Relating to the surgical restoration of a lost or absent part. 2. Of, relating to, or characterized by cells that have become less differentiated. anaplastic 1. lymphoma kinase (ALK) inhibitor, will be presented at the American Association for Cancer Research Wikipedia is not the place for advertisement or self-advertising. The American Association for Cancer Research (AACR) is an organization based in Philadelphia, Pennsylvania, that focuses on all aspects of cancer research including basic, clinical and translational (AACR AACR American Association for Cancer Research AACR Anglo-American Cataloging Rules AACR Australasian Association of Cancer Registries AACR African Armed Conflicts Resolved ) Annual Meeting in Denver, Colorado, being held April 18 to 22, 2009. The schedule and meeting location for the sessions, together with the abstract information, are listed below: Date & Time: Sunday, April 19, 2009, 1:00 PM - 5:00 PM Session Title: Kinase Inhibitors 1 Abstract: #1739 Title: The orally active kinase inhibitor AP24534 has potent activity against the FGF receptor family in multiple cancer models Presenter: Joseph M. Gozgit, Ph.D. (ARIAD Pharmaceuticals) Location: Hall B-F, Poster Section 35, Poster Board 1 Date & Time: Sunday, April 19, 2009, 3:55 PM - 4:10 PM Session Title: Understanding and Targeting Oncogenic oncogenic /on·co·gen·ic/ (-jen´ik) giving rise to tumors or causing tumor formation; said especially of tumor-inducing viruses. on·co·gen·ic or on·cog·e·nous adj. Pathways Abstract: #1887 Title: The mTOR inhibitor deforolimus is efficacious in models of mutant KRAS KRAS Knowledge Representation for Autonomous Systems lung cancer Presenter: Brian Haines, Ph.D. (Merck & Co.) Location: Room 502-504, Oral Presentation Date & Time: Monday, April 20, 2009, 1:00 PM - 5:00 PM Session Title: IGF-IR and PI3K PI3K Phosphatidylinositol-3-Kinase PI3K Phosphoinositide 3-Kinase Pathways Abstract: #2809 Title: Combination treatment with the anti-IGF1R antibody MK-0646 and the mTOR inhibitor deforolimus leads to more effective PI3K pathway targeting and anti-tumor activity Presenter: Sriram Sathyanarayanan, Ph.D. (Merck & Co.) Location: Hall B-F, Poster Section 33, Poster Board 9 Date & Time: Tuesday, April 21, 2009, 8:00 AM -12:00 PM Session Title: Kinase Inhibitors 3 Abstract: #3738 Title: Discovery of potent and selective orally active inhibitors of anaplastic lymphoma kinase (ALK) Presenter: William C. Shakespeare, Ph.D. (ARIAD Pharmaceuticals) Location: Hall B-F, Poster Section 36, Poster Board 22 About ARIAD ARIAD's vision is to transform the lives of cancer patients with breakthrough medicines. The Company's mission is to discover, develop and commercialize small-molecule drugs to treat cancer in patients with the greatest and most urgent unmet medical need - aggressive cancers where current therapies are inadequate. ARIAD's lead product candidate, deforolimus, is an investigational mTOR inhibitor in Phase 3 clinical development in patients with advanced sarcomas and is being developed in collaboration with Merck & Co., Inc. ARIAD's second product candidate, AP24534, is an investigational multi-targeted kinase inhibitor in Phase 1 clinical development in patients with hematological hematological, hematologic pertaining to or emanating from blood cells. hematological tests total and differential white cell counts, hematocrit estimation, erythrocyte count. cancers. ARIAD has an exclusive license to pioneering technology and patents related to certain NF-B cell-signaling activity, which may be useful in treating certain diseases. For additional information about the Company, please visit http://www.ariad.com. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion